Sadnicka, Anna <br/><br/>
Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis.  [electronic resource] 

 -  Journal of neurology, neurosurgery, and psychiatry  Feb 2011 
 - 230-2 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1468-330X 
<br/><br/><label>Standard No.: </label>10.1136/jnnp.2009.174888  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anti-Inflammatory Agents--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Autoimmune Diseases--drug therapy<br/>Electroencephalography<br/>Electromyography<br/>Humans<br/>Immunoglobulins, Intravenous--therapeutic use<br/>Magnetic Resonance Imaging<br/>Male<br/>Methylprednisolone--therapeutic use<br/>Myasthenia Gravis--drug therapy<br/>Neural Conduction--physiology<br/>Neurologic Examination<br/>Plasma Exchange<br/>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating--drug therapy<br/>Rituximab<br/>Syringomyelia--drug therapy<br/>Tomography, X-Ray Computed